Biocytogen Pharmaceuticals (Beijing) (SHA:688796, HKG:2315) plans to raise its capital in its subsidiary, Biocytogen Jiangsu Gene Biotechnology, by 550 million yuan through debt-to-equity conversion, according to a Wednesday disclosure on the Shanghai bourse.
The capital increase will include 165 million yuan as registered capital and 385 million yuan as capital reserve.
After the transaction, Biocytogen Jiangsu's registered capital will increase to 176.1 million yuan from 11.1 million yuan.
The pharmaceutical company's shares dropped less than 3% at the close.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments